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ABSTRACT The nonmevalonate pathway is the sole pathway for isoprenoid biosyn-
thesis in Burkholderia cenocepacia and is possibly a novel target for the development
of antibacterial chemotherapy. The goals of the present study were to evaluate the
essentiality of dxr, the second gene of the nonmevalonate pathway, in B. cenocepacia
and to determine whether interfering with the nonmevalonate pathway increases sus-
ceptibility toward antibiotics. To this end, a rhamnose-inducible conditional dxr knock-
down mutant of B. cenocepacia strain K56-2 (B. cenocepacia K56-2dxr) was con-
structed, using a plasmid which enables the delivery of a rhamnose-inducible
promoter in the chromosome. Expression of dxr is essential for bacterial growth; the
growth defect observed in the dxr mutant could be complemented by expressing
dxr in trans under the control of a constitutive promoter, but not by providing 2-
C-methyl-D-erythritol-4-phosphate, the reaction product of DXR (1-deoxy-D-xylulose
5-phosphate reductoisomerase). B. cenocepacia K56-2dxr showed markedly increased
susceptibility to the -lactam antibiotics aztreonam, ceftazidime, and cefotaxime,
while susceptibility to other antibiotics was not (or was much less) affected; this in-
creased susceptibility could also be complemented by in trans expression of dxr. A
similarly increased susceptibility was observed when antibiotics were combined with
FR900098, a known DXR inhibitor. Our data conﬁrm that the nonmevalonate path-
way is essential in B. cenocepacia and suggest that combining potent DXR inhibitors
with selected -lactam antibiotics is a useful strategy to combat B. cenocepacia in-
fections.
KEYWORDS nonmevalonate pathway, Burkholderia cenocepacia, DXR, Burkholderia
cepacia complex, beta-lactam antibiotics
Isoprenoids are a diverse class of naturally occurring compounds with widely variedroles in physiological processes in all living organisms. Animals (including humans),
fungi, Archaea, and some bacteria synthesize isoprenoids using the mevalonate path-
way (1). An alternative metabolic pathway for the biosynthesis of isoprenoids, the
1-deoxy-D-xylulose-5-phosphate (DOXP) pathway or nonmevalonate pathway, was
discovered in the late 1980s (2). This pathway starts with the condensation of
D-glyceraldehyde-3-phosphate and pyruvate to DOXP, catalyzed by the enzyme DOXP-
synthase (DXS; in Burkholderia cenocepacia strain J2315, encoded by BCAM0911).
Next, DOXP is converted to 2-C-methyl-D-erythritol-4-phosphate (MEP) by DOXP-
reductoisomerase (DXR; encoded by BCAL2085). Subsequently, 4-diphosphocytidyl-2-
C-methyl-D-erythritol (CDP-ME) is formed by CDP-ME synthase (IspD; encoded by
BCAL2016). CDP-ME is then phosphorylated by CDP-ME kinase (IspE; encoded by
BCAL0802), forming CDP-ME-2-phosphate, which is subsequently converted to 2-C-
methyl-D-erythritol-2,4-cyclodiphosphate (MER-cPP) by MER-cPP synthase (IspF, en-
coded by BCAL2015). This cyclic diphosphate molecule is the precursor of isopentenyl
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) (3, 4). The rate-limiting
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step in the nonmevalonate pathway is the conversion of DOXP to MEP, which is
catalyzed by DXR. Fosmidomycin, a natural phosphonic acid antibiotic, and FR900098,
an N-acetyl derivative of fosmidomycin, are effective inhibitors of puriﬁed DXR from
several bacterial species, but often have limited effects on whole bacterial cells (5, 6).
Burkholderia cepacia complex (Bcc) bacteria are highly resistant to most antibiotics
and are most known for their ability to cause life-threatening respiratory tract infections
in cystic ﬁbrosis (CF) patients (7). Bcc bacteria, including B. cenocepacia, use the
nonmevalonate pathway as sole pathway for isoprenoid biosynthesis. As this pathway
is not present in human cells, it is a possible novel target for the development of
antibacterial chemotherapy against Bcc infections (8). DXR (encoded by BCAL2085) was
predicted to be essential in B. cenocepacia (9); a more recent study predicted that all
ﬁve genes of the nonmevalonate pathway would be essential in B. cenocepacia J2315
(10). This makes the enzymes of the nonmevalonate pathway interesting candidates as
drug targets. However, resistance against fosmidomycin, FR900098, and several other
fosmidomycin derivatives was previously observed in a large collection of Bcc strains,
and could partly be explained by the lack of a glycerol-3-phosphate transporter (GlpT)
system, which is required for the import of fosmidomycin and FR900098 (8). However,
Bcc species possess an alternative GlpT system, which can be induced by the addition
of glucose-6-phosphate, leading to increased uptake of fosmidomycin. Unfortunately, a
fosmidomycin resistance gene (fsr), which is involved in efﬂux of fosmidomycin and
FR900098, is upregulated in treated cultures and is able to compensate for the
increased fosmidomycin uptake in the presence of glucose-6-phosphate (8, 11). Iso-
prenoids are precursors for the biosynthesis of hopanoids, which are involved in
regulation of membrane stability, permeability, and ﬂuidity, and which contribute to
the intrinsic resistance of Bcc bacteria against various antibiotics, including polymyxins,
erythromycin, and chlorhexidine (11–13). Deletion of genes (BCAM2831 and BCAS0167)
involved in hopanoid biosynthesis (squalene-hopene cyclases) resulted in the loss of
swarming and swimming motility, suggesting that hopanoids play an important role in
the physiology of B. cenocepacia (13). Several studies provide evidence that reducing
the amount of hopanoids in the membrane of Bcc bacteria can increase susceptibility
to antibiotics (11–15). For example, Malott et al. described resistance of Burkholderia
multivorans isolates to fosmidomycin and colistin when used alone, but they observed
antimicrobial synergy when both antibiotics were used in combination (11).
The goals of the present study were to determine whether dxr is truly essential in B.
cenocepacia and to investigate whether interfering with the nonmevalonate pathway
increased the susceptibility of B. cenocepacia to antibiotics.
RESULTS AND DISCUSSION
Construction of conditional mutants of B. cenocepacia K56-2. We constructed a
B. cenocepacia K56-2 mutant (designated B. cenocepacia K56-2dxr), in which the ex-
pression of dxr (homolog of BCAL2085) is controlled by the rhamnose-inducible pro-
moter Prha. The correct alignment of Prha with dxr was veriﬁed with Sanger sequencing
(see additional data set 1 in the supplemental material). Quantitative real-time PCR
(qPCR) was used to determine dxr expression in K56-2 and K56-2dxr under various
conditions (Fig. 1). In the absence of rhamnose, dxr expression in K56-2dxr is very low
(but not completely switched off), while in the presence of rhamnose, the mRNA
expression level was similar to that observed in the wild-type strain.
Differences in planktonic growth between B. cenocepacia K56-2 and K56-2dxr.
Growth curves of K56-2 and K56-2dxr obtained in a previously described basal salts
medium (BSM-O) (16) in the presence and absence of rhamnose are shown in Fig. 2.
K56-2dxr shows a growth defect, conﬁrming that DXR is essential in K56-2, as previously
suggested (9, 10). Growth was completely inhibited in K56-2dxr if the precultures used
for the growth curves were grown in the absence of rhamnose, but growth resumed
after a delay. Consecutive batch cultures in medium without rhamnose, starting from
a preculture grown in the presence of rhamnose, show that growth is only inhibited
after several generations. The growth rate then recovers to near wild-type levels upon
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further cultivation, and remains at this level (see Fig. S1 in the supplemental material).
This indicates that, after withdrawal of rhamnose, levels of dxr mRNA and/or DXR
protein initially remain sufﬁcient to sustain growth. However, after several generations
the protein is depleted, leading to complete growth inhibition. This is followed by
selection of suppressor mutants, which grow at rates nearly identical to that of the wild
type. The suppressor mutant(s) are most likely “false suppressor mutants,” in which the
rhamnose-inducible promoter and/or its regulators are mutated in such a way that the
conditional dxr expression is converted to constitutive expression (17). Similar growth
proﬁles were observed in other media (see Fig. S2 in the supplemental material),
conﬁrming that the phenotype is not speciﬁc for BSM-O medium. While we did not
evaluate the effect of lack of dxr expression in vivo, it is worth mentioning that in a
synthetic cystic ﬁbrosis medium (18), a growth defect was also observed, suggesting
that under the nutritional conditions encountered in the lungs of CF patients, dxr
expression is important.
The growth defect in K56-2dxr could be complemented by expression of dxr in trans
from a constitutive promoter (Fig. 3). However, growth could not be restored by adding
MEP, the reaction product of DXR (highest concentration tested, 5 mM) (Fig. 4); this is
likely due to a lack of uptake of MEP.
Differences in in vitro antimicrobial susceptibility. MICs of fosmidomycin and
FR900098 were 500 g/ml for B. cenocepacia K56-2 and K56-2dxr, irrespective of
whether rhamnose was present. This is in agreement with concentrations previously
reported for B. cenocepacia strain LMG 16656 (8). Subsequently, we determined the MIC
for a range of antibiotics, for B. cenocepacia K56-2, B. cenocepacia K56-2 in the presence
of subinhibitory concentration of FR900098 (250 M), B. cenocepacia K56-2dxr, B.
cenocepacia K56-2dxr in the presence of rhamnose, and for the complemented strain
(Table 1). Deletion of dxr resulted in an increased susceptibility toward all -lactam
antibiotics tested, with the most pronounced differences for aztreonam (16-fold differ-
ence), the cephalosporin ceftazidime (16-fold), and cefotaxime (32-fold). Although
differences in MIC were also observed for the carbapenems tested, these were lower
(2-fold for meropenem and 4-fold for imipenem). For the other antibiotics, difference in
MIC between the wild type and the dxr mutant were either small (bacitracin, chloram-
phenicol, ciproﬂoxacin, tetracycline, and rifampin) or no difference was observed
(erythromycin and tobramycin). For the wild-type strain, the addition of rhamnose did
not change the MIC of any of the antibiotics tested; the addition of rhamnose to the dxr
mutant returned all MICs to wild-type levels, indicating that the reduced expression of
FIG 1 Relative mRNA expression of dxr measured by qPCR. Expression levels shown are relative to that
of the expression observed in B. cenocepacia K56-2. Error bars represent range; n  2.
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dxr was the cause for the MIC changes (Table 1). Expressing dxr in trans under the
control of a constitutive promoter returned MIC levels of antibiotics (with the exception
of bacitracin) for the dxr mutant back to wild-type levels. Interestingly, when the DXR
inhibitor FR900098 was added along with the antibiotics, MICs for the -lactam
antibiotics were (much) lower and in the same range as that observed for the dxr
mutant (Table 1). Compared to FR900098, the potentiating effect of fosmidomycin was
less pronounced (see Fig. S3 in the suplemental material), which is in line with the
previously observed lower antimicrobial activity of the latter (8).
FIG 2 Growth of B. cenocepacia K56-2 wild type and the K562dxr conditional mutant in permissive and nonpermissive conditions. Top
panels: planktonic growth. Solid squares, K56-2dxr; open circles, K56-2 wild type; orange, BSM-O with 0.5% glucose; blue, BSM-O with
0.5% rhamnose. Absence of rhamnose inhibits growth of K56-2dxr, but growth resumes after a delay (left). Addition of rhamnose
enables growth of the conditional mutant to near wild-type levels. Growth inhibition in the presence of glucose is less pronounced
if precultures are grown in the presence of rhamnose (right). Growth curves are representative of three biological replicates, performed
in 96-well round bottom microtiter plates. Bottom panel: colony formation on agar plates. A, K56-2  pSCrhaB2; B, K56-2dxr. Cultures
grown in BSM-O with 200 mg/liter trimethoprim without addition of sugars were normalized to an optical density at 590 nm (OD590)
of 1.0, and then a 1:10 dilution series was performed. Aliquots of 15 l of the diluted cultures were spotted onto BSM-O (with 200
mg/liter trimethoprim) with 0.5% rhamnose (left) or 0.5% glucose (right).
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The effect of reduced dxr expression or of adding FR900098 was most pronounced
for aztreonam, ceftazidime, and cefotaxime. Aztreonam and cefotaxime both target
penicillin-binding protein (PBP) 3 in Escherichia coli (19, 20). In Burkholderia pseudomal-
lei, the deletion of BSSP1219, the gene encoding a PBP3, results in ceftazidime
resistance, suggesting that ceftazidime targets PBP3; a homolog of BSSP1219 is present
in B. cenocepacia (21). PBP3 is involved in peptidoglycan synthesis, as it is part of the
peptidoglycan synthesis core of the divisome, and it modulates the interaction of FtsW
with lipid II (22). Lipid II [undecaprenyl-pyrophosphoryl-MurNAc-(pentapeptide)-
GlcNAc] is the precursor for peptidoglycan synthesis, and the lipid undecaprenyl
phosphate (C55-P) is synthesized from C5 isopentenyl units (23), which are in turn
produced by the nonmevalonate pathway (24). Interestingly, reduced dxr expression
and the addition of the DXR inhibitor FR900098 also reduced the MIC for bacitracin (by
2- and 4-fold, respectively). Bacitracin inhibits cell wall formation by binding to C55-
isoprenyl pyrophosphate (C55-IPP), which is responsible for transporting peptidoglycan
precursors across the bacterial cell membrane (25). Our data suggest that reducing dxr
expression in B. cenocepacia K56-2 or adding FR900098 (partially) inhibits cytoplasmic
steps of peptidoglycan biosynthesis, leading to lower levels of C55-P and C55-IPP and
increased susceptibility to antibiotics that target interaction partners of C55-P and
C55-IPP. Carbapenems, such as meropenem and imipenem, target PBP2 (26). In contrast
to PBP3 (which is part of the divisome), PBP2 is part of the elongasome (responsible for
FIG 3 Expression of dxr in trans complements the growth defect observed in B. cenocepacia K56-2dxr. Growth medium, LBB
with 200 mg/liter trimethoprim. Orange, 0.5% glucose; blue, 0.5% rhamnose. pDA-dxr expresses dxr constitutively. Growth
curves represent the average of 4 biological replicates, performed in 96-well round bottom microtiter plates.
FIG 4 Growth of B. cenocepacia K56-2dxr in the presence of 2-C-methyl-D-erythritol 4-phosphate (MEP).
Growth medium, BSM-O. Solid squares, K56-2dxr; open circles, K56-2 wild type; orange, 0.5% glucose;
blue, 0.5% rhamnose; yellow, 5 mM MEP.
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elongation of rod-shaped cells) and interacts with several other proteins in the Rod
system (27). The different targets of the -lactam antibiotics tested (PBP2 versus PBP3)
could explain the different effects of reduced dxr expression and the potentiating
activity of FR900098. The genome of B. cenocepacia strain J2315 (very similar to that of
strain K56-2) encodes two PBP3s (BCAM1362 and BCAL3468 genes, 49% similarity);
this likely explains the strain’s extreme resistance to aztreonam (MIC, 2,048 g/ml),
ceftazidime (MIC, 128 g/ml), and cefotaxime (MIC, 2,048 g/ml) observed in B.
cenocepacia (in contrast, for Pseudomonas aeruginosa, EUCAST clinical breakpoints for
aztreonam and ceftazidime are 16 and 8 g/ml, respectively).
Conclusions. Our data conﬁrm that dxr, and by extension the nonmevalonate
pathway, is essential in B. cenocepacia and is a potentially interesting drug target.
Interfering with this pathway, either by reducing the expression of dxr (coding for the
key enzyme DXR) or by inhibiting DXR activity using the acetylated fosmidomycin
derivative FR900098, drastically reduced the MIC of certain -lactam antibiotics. This
was most obvious for -lactam antibiotics that target interaction partners of C55-P and
C55-IPP, explaining the link between reduced isoprenoid synthesis and resistance to
these antibiotics. High concentrations of aztreonam (up to 985 mg/kg sputum) can be
obtained after inhalation therapy (28) and these concentrations are above the MIC that
is obtained in the wild type in combination with FR900098. It will be interesting to
explore whether the combination of carefully selected -lactam antibiotics and DXR
inhibitors could provide an alternative strategy to combat B. cenocepacia infections.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. Bacterial strains and plasmids used in this
study are listed in Table 2. E. coli and B. cenocepacia strains were grown in Luria-Bertani agar or broth
(LBA or LBB) or in more deﬁned and phosphate-buffered media, BSM-O or M9-O (16). BSM-O is based on
a basal salt medium (18.6 mM K2HPO4, 7.2 mM NaH2PO4, 37.4 mM NH4Cl, 0.1 g/liter nitrilotriacetic acid,
0.2 g/liter MgSO4·7 H2O, 0.012 g/liter FeSO4·7 H2O, 0.003 g/liter MnSO4·H2O, 0.003 g/liter ZnSO4·7 H2O,
and 0.001 g/liter CoSO4·7 H2O) (29) and supplemented with yeast extract (5 g/liter), Casamino Acids (2
g/liter), and 0.5% (wt/vol) glycerol (16). M9-O is based on M9 (42 mM Na2HPO4, 22 mM KH2PO4, 8 mM
NaCl, and 10 mM NH4Cl) and was supplemented with the same organic substrates as those for BSM-O.
Media were supplemented with 0.5% (wt/vol) rhamnose or glucose, 50 g/ml gentamicin (Gen), 40
g/ml kanamycin (Kan), trimethoprim (Tmp, 50 or 200 g/ml), or tetracycline (Tet; 20 or 200 g/ml) (all
from Sigma-Aldrich) as required. Liquid cultures were grown in a shaking incubator at 37°C.
Construction of conditional dxr mutant. A conditional knockdown mutant was constructed by
replacing the native promoter of the target gene dxr (BCAL2085 in B. cenocepacia J2315) with the
plasmid-borne rhamnose-inducible promoter Prha (16, 30), using homologous recombination. Primers are
listed in Table 3. The genome contigs of B. cenocepacia K56-2 were obtained from the Burkholderia
Genome Database (http://www.burkholderia.com/; whole genome shotgun sequence of Burkholderia
cenocepacia K56-2Valvano, RefSeq NZ_ALJA02000015). Primers DXR F1/DXR R2 were designed to amplify
TABLE 1MIC values of antibiotics belonging to different classes for B. cenocepacia K56-2,
B. cenocepacia K562dxr, and the complemented mutanta
Antibiotic
MICs (g/ml)b against:
Wild
type
dxr
mutant
Wild type 
rhamnose
dxr mutant 
rhamnose
dxr mutant 
pDA-dxr
Wild type 
FR900098
Aztreonam 2,048 128 2,048 2,048 2,048 64
Ceftazidime 128 8 128 128 256 8
Cefotaxime 2,048 64 2,048 2,048 1,024 16
Meropenem 16 8 16 16 32 8
Imipenem 128 32 128 128 128 32
Bacitracin 32,000 16,000 32,000 32,000 8,000 8,000
Chloramphenicol 32 16 32 32 16 32
Ciproﬂoxacin 4 2 4 4 4 4
Erythromycin 512 512 512 512 512 512
Rifampin 16 32 32 32 32 16
Tetracyclinec 8 4 8 8 2
Tobramycin 256 256 256 256 512 256
aDetermined in the presence and absence of rhamnose (0.5%) or FR900098 (250 M).
bDetermined in LBB.
cThe MIC for tetracycline could not be measured in the dxr mutant expressing dxr in trans, as this plasmid
contains a tetracycline resistance marker.
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a 283-nucleotide (nt) fragment spanning the 5= region of dxr. The fragment was digested with restriction
enzymes XbaI and NdeI (Promega) and ligated into digested pSC200 downstream of Prha, resulting in
plasmid pSC200dxr. The recombinant plasmid was transformed into E. coli DH5 pir with the heat shock
method using LBA supplemented with 50 g/ml Tmp and 0.5% glucose as selective agar. Exconjugants
were screened for presence of insert by PCR using primers rhaF/200-MCS-R. The recombinant plasmid
was transferred into B. cenocepacia K56-2 by triparental mating (16). Overnight liquid cultures of B.
cenocepacia K56-2, E. coli HB101 (pRK2013), and E. coli donor strain were mixed in equal volumes, and
300 l of the mix was spotted onto LBA with 0.5% rhamnose and incubated at 37°C for 6 h. Cells were
washed off the agar with physiological saline and plated on LBA containing 50 g/ml Gen (to select
against E. coli), 200 g/ml Tmp and 0.5% rhamnose. Plates were incubated at 37°C for 48 h, and
exconjugants were screened for correct insertion of the plasmid by PCR using primers rhaF/DXR R4. A
successful exconjugant (here referred to as K56-2dxr) was subcultured on LBA plus 200 g/ml Tmp and
0.5% rhamnose, and the respective PCR product was Sanger sequenced (GATC Biotech, Additional data
set 1).
To allow growth experiments on LBB with Tmp, B. cenocepacia K56-2 wild type was transformed with
a replicative plasmid (pSCrhaB2) carrying the dhfr gene (31).
Construction of B. cenocepacia K56-2dxr expressing dxr in trans. To complement the dxr mutant,
a modiﬁed version of pDAI-SceI, a plasmid used for constitutive I-SceI (homing endonuclease) expression
from the constitutive P1 promoter for dhfrIIb (32), was used. I-SceI was excised using NdeI and XbaI and
the plasmid was gel cleaned. The linear plasmid was then either blunted and self-ligated, giving rise to
the vector control plasmid pDA, or ligated with the dxr gene, ampliﬁed from the B. cenocepacia K56-2
genome using primers dxr-exprF and dxr-exprR and restricted with NdeI and XbaI, giving rise to pDA-dxr.
Correct insertion of dxr was screened by PCR using primers pDA-F and rha1R. Plasmids pDA and
pDA-dxr were transformed into K56-2dxr by triparental mating, using LBA with 200 Tet, 200 Tmp, 50 Gen,
and 0.5% rhamnose as selective medium. dxr on pDA-dxr of a successful exconjugant of K56-2dxr was
Sanger-sequenced (GATC Biotech, Additional data set 1).
RNA extraction and cDNA synthesis. Cells of wild-type and mutant B. cenocepacia K56-2 were
cultured in either M9-O or LBB. Both media were supplemented with 0.5% rhamnose or glucose as
required. After 24 h incubation at 37°C, cells were collected by centrifugation and RNA was extracted
using the RiboPure bacteria kit (Ambion) according to the manufacturer’s instructions. RNA concentra-
TABLE 2 Bacterial strains and plasmids
Strain or plasmid Characteristic(s) Reference or source
B. cenocepacia strain
K56-2 Wild type, ET-12 lineage, CF isolate Lab collection
K56-2dxr K56-2 Prha::dxr This study
K56-2dxr  pDA- K56-2dxr vector control for complementation experiments This study
K56-2dxr  pDAdxr K56-2dxr, complemented with constitutively expressed dxr This study
K56-2  pSCrhaB2 Wild type, transformed with a plasmid conveying Tmp resistance This study
E. coli strains
DH5 For propagation of replicative plasmids pDA- and pDA-dxr Lab collection
DH5 pir pir, for propagation of suicide plasmid pSC200 and its derivatives Biomedal
HB101 pRK2013; helper strain for triparental matings Lab collection
Plasmids
pRK2013 oricolE1, RK2 derivative, Kanr, mob, tra 35
pSC200 pGpTp derivative, oriR6K, rhaR, rhaS, Prha, e-gfp, dhfr, Tmpr 16
pSC200dxr pSC200 carrying fragment of dxr This study
pDA Derivative of pDAI-SceI, oripBBR1, Tetr, I-SceI gene removed and self-ligated This study
pDA-dxr pDA carrying the dxr gene under a constitutive dhfr promoter This study
pSCrhaB2 oripBBR1, rhaR, rhaS, PrhaB, Tmpr, mob 31
TABLE 3 Primers
Name Sequencea Purpose
DXR F1 TTATTAATACATATGCAAAAACGTCTGACATTGCTC Ampliﬁcation of dxr fragment
DXR R2 TATCTAGAAGCCGTCGCTCTTCGACAC Ampliﬁcation of dxr fragment
rhaF CACGTTCATCTTTCCCTGGT Conﬁrmation of fragment insertion and plasmid recombination
200-MCS-R AACACTTAACGGCTGACATGG Conﬁrmation of insertion of fragment in plasmid
DXR R4 AGGCCCTTGTTCATCATCG Conﬁrmation plasmid recombination in K56-2dxr
dxr-exprF AATAATAATCATATGCAAAAACGTCTGACATTGCTC Ampliﬁcation of dxr for complementation
dxr-exprR AATTCTAGATTCATGAGCACCCCATTCAGAC Ampliﬁcation of dxr for complementation
pDA-F GCAACTGGTCCAGAACCTTG Conﬁrmation of dxr insertion into pDA
rha1R CTCTCATCCGCCAAAACAGC Conﬁrmation of dxr insertion into pDA
aRestriction sites are underlined.
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tions were determined using a BioDrop lite (Isogen Life Science), and 500 ng of each RNA sample was
used to synthesize cDNA using the qScript cDNA synthesis kit (QuantaBio).
Quantitative real-time PCR (qPCR). qPCR experiments were performed on a Bio-Rad CFX96
real-time PCR detection system using the Perfecta SYBR green Fastmix (QuantaBio), according to the
manufacturer’s instructions. The PCR cycling protocol included an initial denaturation at 95°C for 3 min,
followed by 40 ampliﬁcation cycles consisting of 15 s at 95°C and 1 min at 60°C; a melting curve analysis
was performed at the end of each run. All PCR data were normalized to the mean expression value of
three reference genes (BCAS0175, BCAM2784, and BCAL2694) that were stably expressed under all
conditions (33).
Growth curves. Bacterial cultures were grown overnight in LBB supplemented with 200 g/ml Tmp
and 0.5% rhamnose as required and subsequently diluted to a ﬁnal inoculum of 5  105 CFU/ml in
various growth media, including LBB, BSM-O, M9-O, M9 with 0.5% glucose, tryptic soy broth (TSB),
Mueller-Hinton broth (MHB), and synthetic cystic ﬁbrosis medium (SCFM; [18]). 2-C-Methyl-D-erythritol
4-phosphate lithium salt (MEP) was purchased from Sigma-Aldrich and added to a ﬁnal concentration of
5 mM. Glucose and rhamnose were added to a ﬁnal concentration of 0.5% as required. A total of 200 l
of each bacterial suspension was added in duplicate to a ﬂat-bottomed 96-well microtiter plate (SPL Life
Sciences), and bacterial growth was monitored by measuring absorbance at 590 nm in an Envision
multilabel plate reader (PerkinElmer, Waltham, MA), every 30 min for 48 to 72 h at 37°C, until the
stationary phase was reached. Growth curves for consecutive reinoculated batch cultures were per-
formed in a Cell Growth Quantiﬁer (Aquila Biolabs).
Evaluation of in vitro antimicrobial susceptibility. Antimicrobial susceptibility was investigated by
determination of the MIC according to the EUCAST broth microdilution guidelines (34). Antibiotics tested
included bacitracin, cefotaxime, ceftazidime, chloramphenicol, ciproﬂoxacin, erythromycin, imipenem,
rifampin, tetracycline, and FR900098 (Sigma-Aldrich), meropenem (Hospira Benelux), tobramycin, aztreo-
nam (TCI Europe), and fosmidomycin (Invitrogen). MICs were determined in triplicate using ﬂat-
bottomed 96-well microtiter plates, with concentrations adapted to the high antimicrobial resistance of
B. cenocepacia. Planktonic bacterial cultures were grown overnight in the appropriate medium and
added to the 96-well plates at a ﬁnal inoculum of 5 105 CFU/ml. Plates were incubated for 24 h at 37°C,
and absorbance was measured at 590 nm using an Envision plate reader. Initial tests for the potentiating
effect of fosmidomycin and FR900098 were performed in MHB, with concentrations of potentiator
ranging from 4 to 500 M. Further MIC analyses were then conducted with FR900098 at a concentration
of 250 M, because this showed the highest effect on MIC values, and in LBB, because the comple-
mented mutants did not grow in MHB. Neither Tmp nor Tet was added to the MIC tests.
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